Adial Financial Statements From 2010 to 2025

ADIL Stock  USD 0.22  0.01  4.35%   
Adial Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Adial Pharmaceuticals' valuation are provided below:
Market Capitalization
6.1 M
Earnings Share
(0.60)
There are over one hundred nineteen available fundamental signals for Adial Pharmaceuticals, which can be analyzed over time and compared to other ratios. We recommend to validate Adial Pharmaceuticals' prevailing fundamental drivers against the all of the trends between 2010 and 2025. Market Cap is expected to rise to about 22.5 M this year. Enterprise Value is expected to rise to about 18.9 M this year
Check Adial Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adial Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 187.6 K, Depreciation And Amortization of 537 or Interest Expense of 758.1 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 4.85. Adial financial statements analysis is a perfect complement when working with Adial Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Adial Stock
Check out the analysis of Adial Pharmaceuticals Correlation against competitors.
For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.

Adial Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets4.6 MM2.9 M
Slightly volatile
Other Current Liabilities712.4 K725.7 K454.2 K
Slightly volatile
Total Current Liabilities1.1 M975.9 K695.4 K
Slightly volatile
Accounts Payable250.6 K250.1 K169.8 K
Slightly volatile
Cash3.5 M3.8 M2.3 M
Slightly volatile
Non Current Assets Total555 K985.2 K353.4 K
Slightly volatile
Other Assets422.6 K402.5 K205.7 K
Slightly volatile
Cash And Short Term Investments3.5 M3.8 M2.3 M
Slightly volatile
Common Stock Total Equity12.3 K13 K4.3 M
Slightly volatile
Common Stock Shares Outstanding19.5 M18.6 M2.7 M
Slightly volatile
Liabilities And Stockholders Equity4.6 MM2.9 M
Slightly volatile
Other Current Assets486.8 K308.2 K334 K
Slightly volatile
Total Liabilities1.3 M975.9 K839 K
Slightly volatile
Total Current AssetsM4.1 M2.6 M
Slightly volatile
Short Term Debt48.6 K51.1 K89.3 K
Very volatile
Intangible Assets4.7 K3.3 K6.6 K
Slightly volatile
Common Stock6.1 K6.5 K4.2 M
Slightly volatile
Short and Long Term Debt Total277.6 K186.6 K264.7 K
Very volatile
Net Receivables28.1 K31.6 K34.5 K
Slightly volatile
Short and Long Term Debt507.9 K792.7 K485.3 K
Slightly volatile
Capital Stock10 K6.5 K9.5 K
Slightly volatile
Other Liabilities829.9 K933.7 KM
Slightly volatile
Current Deferred Revenue1.9 M2.1 M2.3 M
Slightly volatile
Non Current Liabilities Other602.4 K442.8 K887.3 K
Slightly volatile
Property Plant Equipment243.5 K273.9 K298.7 K
Slightly volatile

Adial Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income187.6 K178.7 K42.8 K
Slightly volatile
Depreciation And Amortization537565K
Pretty Stable
Selling General Administrative5.1 M5.1 M3.4 M
Slightly volatile
Other Operating Expenses8.1 M8.3 M5.4 M
Slightly volatile
Research Development2.8 M3.2 M1.9 M
Slightly volatile
Cost Of Revenue5375657.7 K
Slightly volatile
Total Operating Expenses8.1 M8.3 M5.4 M
Slightly volatile
Reconciled Depreciation53756511.5 K
Slightly volatile
Selling And Marketing Expenses451508553
Slightly volatile

Adial Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings21.4 K22.5 K121.5 K
Slightly volatile
Stock Based Compensation757 K796.8 K1.4 M
Slightly volatile
Begin Period Cash Flow3.2 M2.8 M2.2 M
Slightly volatile
Depreciation5375657.7 K
Slightly volatile
Total Cash From Financing Activities6.2 M7.8 MM
Slightly volatile
End Period Cash Flow3.5 M3.8 M2.3 M
Slightly volatile
Change To Netincome7.2 M6.8 M2.9 M
Slightly volatile
Issuance Of Capital Stock5.2 MM6.3 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables219.1 K188.8 K239.5 K
Pretty Stable
Capex To Depreciation11.4 K10.9 K2.9 K
Slightly volatile
Payables Turnover0.00930.00510.0098
Slightly volatile
Cash Per Share0.190.20184.1424
Pretty Stable
Days Payables Outstanding108.3 K74.2 K88.5 K
Slightly volatile
Income Quality0.50.52450.6027
Pretty Stable
Intangibles To Total Assets6.0E-47.0E-40.0335
Slightly volatile
Current Ratio5.984.15924.9832
Pretty Stable
Capex Per Share4.524.31.2136
Slightly volatile
Average Receivables14 K15.8 K17.2 K
Slightly volatile
Interest Debt Per Share0.210.221.2954
Slightly volatile
Debt To Assets0.03950.04161.9414
Pretty Stable
Days Of Payables Outstanding108.3 K74.2 K88.5 K
Slightly volatile
Ebt Per Ebit0.921.5931.0873
Pretty Stable
Quick Ratio5.984.15924.9832
Pretty Stable
Net Income Per E B T0.851.061.0144
Pretty Stable
Cash Ratio5.123.84334.1853
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.810.90.9866
Slightly volatile
Debt Ratio0.03950.04161.9414
Pretty Stable

Adial Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap22.5 M18.8 M20.4 M
Very volatile

Adial Fundamental Market Drivers

Adial Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Adial Pharmaceuticals Financial Statements

Adial Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Adial Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue2.1 M1.9 M
Cost Of Revenue 565.00  536.75 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Adial Pharmaceuticals is a strong investment it is important to analyze Adial Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adial Pharmaceuticals' future performance. For an informed investment choice regarding Adial Stock, refer to the following important reports:
Check out the analysis of Adial Pharmaceuticals Correlation against competitors.
For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.60)
Return On Assets
(0.79)
Return On Equity
(1.55)
The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.